We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Handheld Fluorescent Immunoassay Analyzer for Rapid POC Testing to Transform Clinical Diagnostics

By LabMedica International staff writers
Posted on 17 Jul 2023
Print article
Image: The AF-100S automated, compact, and affordable fluorescent Immunoassay (FIA) solution (Photo courtesy of Anbio)
Image: The AF-100S automated, compact, and affordable fluorescent Immunoassay (FIA) solution (Photo courtesy of Anbio)

An automated, compact, and affordable fluorescent Immunoassay (FIA) solution is designed to transform the landscape of clinical point-of-care (POC) diagnostics.

Anbio Biotechnology (Frankfurt, Germany) has launched the new AF-100S FIA Solution, a compact, handheld solution for point-of-care immunodiagnostic needs that delivers rapid, accurate, and reliable results. The innovative analyzer is capable of detecting a broad spectrum of analytes, such as hormones, enzymes, and infectious diseases, making it a versatile diagnostic tool. Its compact design, lasting battery life, and user-friendly interface make it a practical choice for diverse environments. Its high sensitivity and specificity guarantee that patients are provided accurate results.

The AF-100S employs fluorescently labeled antibodies or antigens to identify specific biomolecules in a patient's sample. When a sample is combined with these labeled antibodies or antigens, the biomolecule, if present, binds to these labeled molecules, creating a complex that releases a fluorescent signal. This signal is then measured and compared with a recognized standard to ascertain the biomolecule's concentration in the sample.

This small yet efficient FIA analyzer can perform up to 240 tests per hour, making it a good fit for high-volume settings. It is powered by a lithium battery that supports up to 800 tests per charge or offers 20 days of device standby time. Its user-friendly interface, shown on a large color touchscreen, simplifies operation. The compact size of the AF-100S, measuring just 195x100x70mm, makes it an optimal choice for various medical settings such as private clinics, urgent care centers, emergency departments, and ambulances.

"The Anbio AF-100S is set to transform the field of clinical diagnostics, empowering healthcare providers with a cost-effective and comprehensive solution," said Sa Jiang, Chief Marketing Officer at Anbio. "Our FIA solution is small, yet powerful point-of-care immunodiagnostic solution that provides rapid, accurate, and reliable results for a wide range of analytes to provide faster diagnosis and better prognosis to patients."

Related Links:
Anbio Biotechnology

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Rickettsia Conorii Assay
RICKETTSIA CONORII ELISA

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Molecular Diagnostics

view channel
Image: Researchers have found the first evidence of testing for the alpha-synuclein protein in blood samples via seed amplification assay (Photo courtesy of Shutterstock)

Blood Test to Detect Alpha-Synuclein Protein Could Revolutionize Parkinson's Disease Diagnostics

Currently, Parkinson's disease (PD) is identified through clinical diagnosis, typically at a later stage in the disease's progression. There is a pressing need for an objective and quantifiable biomarker... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Microbiology

view channel
Image: Ultra-Rapid Antimicrobial Susceptibility Testing (uRAST) revolutionizing traditional antibiotic susceptibility testing (Photo courtesy of Seoul National University)

Ultra-Rapid Culture-Free Sepsis Test Reduces Testing Time from Days to Hours

Sepsis, a critical emergency condition, results from an overactive inflammatory response to pathogens like bacteria or fungi in the blood, leading to organ damage and the possibility of sudden death.... Read more

Pathology

view channel
Image: The AI model can distinguish different stages of DCIS from inexpensive and readily available breast tissue images (Photo courtesy of David A. Litman/Shutterstock)

AI Model Identifies Breast Tumor Stages Likely To Progress to Invasive Cancer

Ductal carcinoma in situ (DCIS) is a non-invasive type of tumor that can sometimes progress to a more lethal form of breast cancer and represents about 25% of all breast cancer cases. Between 30% and 50%... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.